Resources

Publications

Coronavirus Pre-Prints and Publications

COVID-19

• Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
  The New England Journal of Medicine, Keech, Cheryl, et al.

• SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice
  Disclaimer: Pre-print only and not yet published in peer-reviewed article

• First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
  Disclaimer: Pre-print only and not yet published in peer-reviewed article

• Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
  Disclaimer: Pre-print only and not yet published in peer-reviewed article

MERS

• Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
  Vaccine, Smith, Gale, et al.

Flu Publications

• Hemagglutinin from multiple divergent influenza A and B viruses bind to a distinct branched, sialylated poly-LacNAc glycan by surface plasmon resonance
  Vaccine, Hahn, Timothy J. et al
• Comparison of the Safety and Immunogenicity of a Novel Matrix-M-adjuvanted Nanoparticle Influenza Vaccine with a Quadrivalent Seasonal Influenza Vaccine in Older Adults: A Randomized Controlled Trial
  Disclaimer: Pre-print only and not yet published in peer-reviewed article
• Induction of Cross-reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine
  medRxiv, Shinde, Vivek, et al
• Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine
  New England Journal of Medicine, Shinde, Vivek, et al
• Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA
  Vaccine, Portnoff, Alyse, et al
• Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes
  Vaccine, Smith, Gale, et al.
• Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets
  Vaccine, Liu, Ye, et al.
• A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine
  The New England Journal of Medicine, Fries, Louis, et al.
• Rapid Manufacture and Release of a GMP Batch of Avian Influenza A(H7N9) Virus-Like Particle Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology
  BioProcessing Journal, Hahn, Timothy J. et al
• Development of influenza H7N9 virus like particle (VLP) vaccine Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus
  Vaccine, Smith, Gale, et al.

RSV Publications

• Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity
  Vaccine, Patel, Nina, et al.
• Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants
  The New England Journal of Medicine, Madhi, S.A., et al.
• Severe Morbidity and Short- and Mid- to Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection
  Journal of Infectious Diseases, Shinde, Vivek, et al
• Prediction of serious RSV‐related outcomes in older adults with outpatient RSV respiratory illness during 12 consecutive seasons
  Wiley Online, Shinde, Vivek, et al
• Severe Morbidity and Mortality Associated with Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults
  Bradley Ackerson, Hung Fu Tseng, Lina S. Sy, Zendi Solano, Jeff Slezak, Yi Luo, Christine A. Fischetti, Vivek Shinde
• Why Making a Diagnosis of Respiratory Syncytial Virus Should Matter to Clinicians
  Angela R. Branche, MD
• Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
  Immun Ageing, Fries, L, et al.
• The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review
  PLOS ONE, Shinde, Vivek, et al.
• A Phase 2 Randomized, Observer-blind, Placebo-controlled, Dose-ranging trial of Aluminum-Adjuvanted Respiratory Syncytial Virus F Particle Vaccine Formulations in Healthy Women of Childbearing Age
  Vaccine, August, Allison, et al.
• Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs
  Vaccine, Glenn, Gregory M., et al.
• A Randomized, Blinded, Controlled, Dose-Ranging Study of a  Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age
  Journal of Infectious Diseases, Glenn, Gregory M., et al.
• An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization
  Vaccine, Raghunandan, Rama, et al.
• Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats
  PLOS ONE, Smith, Gale, et al.
• Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
  Vaccine, Glenn, Gregory M., et al.

Ebola Publications

• Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice
  Vaccine, LövgrenBengtsson, Karin, et al.
• Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology
  BioProcessing Journal, Hahn, Timothy, et al.

Adjuvant Publications

• Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M
  Vaccine, LövgrenBengtsson, Karin, et al.
• Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice
  Vaccine, Magnusson, Sofia E., et al.
• T-helper 1 cells elicited by H5N1 vaccination predict seroprotection
  J Infect Dis., Pedersen G.K., et al.
• Matrix-M™ Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of Antigen
  PLOS ONE, Reimer, Jenny M., et al
• High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge
  Vaccine, Picard, Michele D., et al.  

Posters

Scientific Posters

2018

11th International Respiratory Syncytial Virus Symposium

• Antigenic Characterization of RSV Pre-fusogenic F Nanoparticle Vaccine, Pre-F, and Post-F Proteins against a Broad Range of Neutralizing Monoclonal Antibodies and Epitope Responses in Cotton Rats
• Binding Kinetics of RSV Pre-fusogenic F Nanoparticle Vaccine to Palivizumab and Serum Polyclonal Antibody
• Feasibility Evaluation of Blow Fill Seal Process and Compatibility with Aluminum Phosphate Adjuvanted Recombinant RSV F Nanoparticle Vaccine
• In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine
• Respiratory Syncytial Virus (RSV) Pre-fusogenic F Nanoparticle Vaccine Compared to Pre-fusion F and Post-fusion F Proteins

Presentations

Scientific Presentations

2020

2020 World Vaccine Congress Europe

• Recombinant nanoparticle COVID-19 vaccine: Platform technology for Emerging Infectious Diseases (EID)

World Vaccine Congress Washington 2020

• Recombinant nanoparticle COVID-19 vaccine: Platform technology for EID (Emerging Infectious Diseases)

• Phase 3 and beyond: Maternal RSV & older adult influence vaccine program

• New Phase 2 NanoFlu data (features new cell-mediated immunity data)

NVX-CoV2373 COVID-19 Vaccine Candidate Phase 1/2, Part 1, Clinical Trial Results

• NVX-CoV2373 COVID-19 Vaccine Candidate Phase 1/2, Part 1, Clinical Trial Results

2nd ISV COVID-19 Vaccines Virtual Congress

• Progress with the Full Length Recombinant Spike Protein Nanoparticle Vaccine

New York Academy of Sciences: Innovations in Maternal, Neonatal, and Early Infancy Vaccines

• Learnings from a Phase 3 RSV Clinical Trial

World Vaccine Congress Webinar

• NVX-CoV2373 Vaccine for COVID-19

NanoFlu Phase 3 Topline Data

• NanoFlu Phase 3 Topline Data

2019

OPTIONS X for the Control of Influenza Conference

• Induction of broadly cross-reactive immune responses against A(H3N2) viruses: results of a phase 2 trial of a novel recombinant hemagglutinin saponin-adjuvanted nanoparticle influenza vaccine (“NanoFlu”)

• Towards an Improved Wild-type Sequence Based Hemagglutination Inhibition Assay (HAI) for the Evaluation of Influenza Vaccines: Challenges and New Developments

Infectious Diseases Society for Obstetrics and Gynecology

• Safety of Third Trimester Immunization with a Respiratory Syncytial Virus (RSV) F Protein Vaccine and Protection of Infants over the First 180 Days of Life Against All-Cause Lower Respiratory Tract Infection

European Society for Pediatric Infectious Diseases

• Phase 3 Prepare Study: Efficacy and Safety of an RSV Vaccine Administered to Pregnant Women for the Prevention of RSV Lower Respiratory Tract Infection in Infants

World Vacinne Congress

• Phase 3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization

2018

11th International Respiratory Syncytial Virus Symposium

• Magnitude and Durability of Anti-F IgG and Palivizumab-Competitive Antibody (PCA) Responses One Year Following Immunization with RSV F NanoparticleV
• Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness (RSV LRTI) in Infants

World Vaccine Congress Europe

• Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus Lower Respiratory Tract Illness in Infants
• Progress Towards an Improved Seasonal Influenza Vaccine: NanoFlu - Nanoparticle Influenza Vaccine (NIV)

IDWeek

• Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) in Infants

Universal Influenza Vaccines (UIV)  

• Data from Completed Phase 1/2 Trial of a Novel Recombinant Saponin-Adjuvanted tNIV

World Vaccine Congress 

• RSV F Nanoparticle Vaccine: IVM
• Nanoparticle Influenza Vaccine: Older Adults

2016

Keystone Symposia: New Approaches to Vaccines for Human and Veterinary Tropical Diseases

• Recombinant Nanoparticle Vaccines: Respiratory and Emerging Viruses

2015

WHO 5th Teleconference on Ebola Vaccine Clinical Trials

• Novavax Ebola/Makona Glycoprotein (GP) Nanoparticle Vaccine Candidate Update: NHP and Clinical Data

WHO Briefing

• Recombinant Nanoparticle Vaccine Using Ebola Guinea 2014 GP Sequence

Atlantic Vaccines Summit & Immunotherapeutics Summit

• Rapid Responses to Novel Lethal Viruses

World Vaccine Congress

• RSV F Nanoparticle Vaccine
• Rapid Responses to Novel Lethal Viruses

7th International Symposium on Filoviruses

• Recombinant EBOV/Makona Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9 Insect Cells

FIGO World Congress of Gynecology and Obstetrics

• RSV F Vaccine: Phase 2 Clinical Trial to Protect Infants via Maternal Immunization

ISBioTech Meeting

• EBOV/Makona Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9 Insect Cells
• Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology